Released Mar 30, 2021, after the close
10-K filed Mar 30, 2021, 89 days after period end · 0001564590-21-016653
Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.48M$1.48M derived−48.0% vs Q4 2019−0.4% vs Q3 2020
Net Income-$721.00K-$721.00K derivedN/M vs Q4 2019N/M vs Q3 2020
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$733,000N/M
Operating Cash Flowderived-$311,000N/M
Free Cash Flowderived-$315,000N/M
Margins · derived
Operating margin-49.7%+37.9 pt vs Q4 2019
Net margin-48.9%+46.8 pt vs Q4 2019
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures | Q4 2017dderived from reported figures |
|---|---|---|---|---|
| Revenue | $1.48M | $2.84M | $2.22M | $1.84M |
| Net Income | -$721.00K | -$2.71M | -$1.03M | -$1.39M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
International Stem Cell CORP · CIK 1355790 · Engraved from SEC EDGAR